Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

被引：0
|
作者：
Gaulin, J. [1 ]
Kotb, R. [1 ]
Turcotte, E. [2 ]
Berard, G. [3 ]
Sawan, B. [4 ]
Schmutz, G. [5 ]
Beauregard, P. [1 ]
机构：
[1] CHU Sherbrooke, Dept Hematol & Oncol, Sherbrooke, PQ J1H 5N4, Canada
[2] CHU Sherbrooke, Dept Nucl Med, Sherbrooke, PQ J1H 5N4, Canada
[3] CHU Sherbrooke, Dept Clin Pharm, Sherbrooke, PQ J1H 5N4, Canada
[4] CHU Sherbrooke, Dept Pathol, Sherbrooke, PQ J1H 5N4, Canada
[5] CHU Sherbrooke, Dept Radiol, Sherbrooke, PQ J1H 5N4, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Colorectal cancer; bevacizumab; third-line therapy; FLUOROURACIL FAILURE; RANDOMIZED-TRIAL; PLUS IRINOTECAN; OXALIPLATIN; LEUCOVORIN; CETUXIMAB; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bevacizumab is Currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness Of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [1] Is there a third-line therapy for metastatic colorectal cancer?
    Grothey, Axel
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (06) : S36 - S38
  • [2] Third-Line Therapy in Metastatic Colorectal Cancer
    van de Haar, Joris
    Valeri, Nicola
    Voest, Emile E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 190 - 191
  • [3] Third-line therapy for metastatic colorectal cancer
    M. G. Gundgaard
    J. B. Soerensen
    E. Ehrnrooth
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 61 : 1 - 13
  • [4] Third-line therapy for metastatic colorectal cancer
    Gundgaard, M. G.
    Soerensen, J. B.
    Ehrnrooth, E.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 1 - 13
  • [5] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [6] Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as second line, third-line or later treatment in metastatic colorectal cancer (MCRC) patients
    Lievre, A.
    Samalin, E.
    Senesse, P.
    Boyer-Gestin, C.
    Mitry, E.
    Lepere, C.
    Bachet, J.
    Vaillant, J.
    Ychou, M.
    Rougier, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    [J]. JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
  • [8] Metastatic Colorectal Cancer: Strategies for Third-Line Treatment
    Marshall, John L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 7 - 15
  • [9] Efficacy and safety of regorafenib as third-line therapy in metastatic colorectal cancer: An indirect meta-analysis
    Wu, Yinying
    Fan, Yangwei
    Dong, Dan Feng
    Dong, Xuyuan
    Hu, Yuan
    Shi, Yu
    Jing, Jiayu
    Li, En Xiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Refining the Use and Sequencing of Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Grothey, Axel
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 14
12345